IgG4 Related Disease Pipeline Analysis Report 2026

IgG4 related disease (IgG4-RD) is a chronic inflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells, leading to fibrosis and organ dysfunction. As per Haralampos M. Moutsopoulos et al., 2025, the disease accounts for around 0.78-1.39 cases per 100,000 person-years. The growing focus on targeted biologics and immunomodulatory therapies is driving innovation in IgG4 related disease therapeutics. According to the IgG4 related disease pipeline analysis, several novel therapeutic products are under development, with monoclonal antibodies and B-cell inhibitors showing promising potential for significant growth in the coming years, supported by increasing clinical trials and expanding research in targeted immune modulation.

Report Coverage

The IgG4 Related Disease Pipeline Analysis Report gives comprehensive insights into IgG4 related disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for IgG4 related disease. The IgG4 related disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The IgG4 related disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with IgG4 related disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to IgG4 related disease.

IgG4 Related Disease Pipeline Outlook

Immunoglobulin G4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by chronic inflammation and fibrosis. It is caused by dysregulated B cell activity and can affect multiple organs simultaneously. It often mimics other conditions, complicating diagnosis, like complexities observed in metastatic urothelial carcinoma diagnosis and treatment landscape. The disease arises when B cells overproduce IgG4 antibodies, leading to immune dysfunction and tissue damage over time.

IgG4-related disease treatment typically includes corticosteroids or B cell-targeting therapies to reduce inflammation and prevent organ damage. Recent advancements focus on more targeted biologics with fewer side effects than traditional treatments. For instance, in June 2024, UPLIZNA® (inebilizumab-cdon) became the first FDA-approved therapy for IgG4-related disease, targeting CD19+ B cells to reduce immune-driven inflammation.

IgG4 Related Disease Epidemiology

Immunoglobulin G4-related disease is increasingly recognized as a rare but significant condition. According to Haralampos M. Moutsopoulos et al., 2025, the incidence is estimated at 0.78-1.39 per 100,000 person-years. As per Rare Diseases Advisor, U.S. epidemiologists found the point prevalence to be 5.3 per 100,000 persons in 2019. The mortality rate was reported as 3.42 per 100 person-years. According to Salma El Aouadi et al., 2025, Japan reports a prevalence of 6 to 30 per 100,000 individuals.

IgG4 Related Disease - Pipeline Therapeutic Assessment

This section of the report covers the analysis of IgG4 related disease drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The IgG4 related disease pipeline analysis report covers 50+ drug analyses based on drug classes:

• Monoclonal Antibodies
• Small Molecules
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

IgG4 Related Disease Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 40% covers a major share of the total IgG4 related disease clinical trials, reflecting strong mid-stage clinical validation and improving success probability, which can accelerate commercialization in the IgG4 related disease market. Phase I hold 20% indicates early innovation and novel mechanisms. Phase III, with 25% supports late-stage approvals and market entry, while early phase I at 15% highlights emerging research activity, strengthening long-term pipeline sustainability.

IgG4 Related Disease Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the IgG4 related disease pipeline analysis include monoclonal antibodies, small molecules, and peptides. The IgG4 related disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for IgG4 related disease. Bruton’s tyrosine kinase (BTK) inhibitors are gaining attention in the IgG4-related disease pipeline for their immune-modulating potential. For instance, rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation in the United States. It demonstrated promising results in reducing disease flare and dependency on glucocorticoids in a phase 2a clinical study involving IgG4-related disease patients.

IgG4 Related Disease Clinical Trials - Key Players

The report for the IgG4 related disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed IgG4 related disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in IgG4 related disease clinical trials:

• Zenas BioPharma (USA), LLC
• Acepodia Biotech, Inc.
• Shenzhen Pregene Biopharma Co., Ltd.
• Amgen
• Immunotech (Beijing) Biotechnology Co., Ltd.
• Xencor, Inc.
• Principia Biopharma
• Bristol-Myers Squibb
• Celgene Corporation
• Genentech, Inc.

IgG4 Related Disease - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for IgG4 related disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of IgG4 related disease drug candidates.

ACE1831

ACE1831 is an allogeneic gamma delta T cell therapy developed by Acepodia Biotech, Inc., currently being evaluated for IgG4-related disease under a Phase 1b/2a clinical trial. This study aims to assess the safety, efficacy, and persistence of ACE1831 in affected individuals. The drug leverages bioorthogonal chemistry to attach CD20-targeting antibodies to T cells, offering a scalable, off-the-shelf alternative to autologous CAR-T therapies.

PRG-1801

PRG-1801 is a BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapy, currently being evaluated for its safety and efficacy in patients with refractory lupus nephritis and IgG4-related disease. Sponsored by Tongji Hospital, this early Phase 1 trial aims to explore and expand dosing while assessing initial safety outcomes. Originally developed for multiple myeloma, PRG-1801 is now being repurposed for autoimmune conditions.

PRG-2311

PRG-2311 is being developed as a dual-targeting CAR-T cell therapy sponsored by Tongji Hospital and is currently being evaluated in an early phase 1 clinical trial. The study examines the safety, efficacy, and dose expansion of this therapy in patients with refractory lupus nephritis and IgG4-related disease. PRG-2311 is targeting CD19 and BCMA-expressing B cells, working by reprogramming T cells to eliminate pathogenic immune cells. The therapy is being administered intravenously. The trial is expected to be completed by July 2028, with ongoing recruitment and active clinical assessment.

Key Questions Answered in the IgG4 Related Disease Pipeline Insight Report

• Which companies/institutions are leading IgG4 related disease drug development?
• Which company is leading the IgG4 related disease pipeline development activities?
• What is the current IgG4 related disease commercial assessment?
• What are the opportunities and challenges present in the IgG4 related disease pipeline landscape?
• What is the efficacy and safety profile of IgG4 related disease pipeline drugs?
• Which company is conducting major trials for IgG4 related disease drugs?
• Which companies/institutions are involved in IgG4 related disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in IgG4 related disease?

Reasons To Buy This Report

The IgG4 Related Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for IgG4 related disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into IgG4 related disease collaborations, regulatory environments, and potential growth opportunities.